[Multicentre clinical trial on efficacy and safety of domestic piperacillin/tazobactam for treatment of acute bacterial infections].
To compare the efficacy and safety of domestic piperacillin/tazobactam with those of Timentin in treatment of acute bacterial infections. A randomized controlled multicentre trial and an opening clinical trial were conducted in 4 hospitals in Beijing. The cure and efficacy rates in the test group were 73.0% (46/63) and 96.8% (61/63), respectively and the bacterial clearance rate was 91.7% (55/60). The cure and efficacy rates in the control group were 58.7% (37/63) and 97.7% (43/44) respectively, and the bacterial clearance rate was 87.9% (51/58). The difference between the two groups was not statistically significant. The cure rate, efficacy rate and bacterial clearance rate in the opening group were 72.7% (32/44), 97.7% (43/44) and 88.4% (38/43) respectively. No serious adverse drug reaction was found during the treatment with piperacillin/tazobactam. Domestic piperacillin/tazobactam is effective and safe for the treatment of acute bacterial infections.